Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

Journal of Crohn's and Colitis

Volumn 7, Issue 2, 2013, Pages 154-160

  Baert, Filip ^a   Glorieus, Elien ^b   Reenaers, Cathérine ^c   D'Haens, Geert ^d,e   Peeters, Harald ^b   Franchimont, Dennis ^f   Dewit, Olivier ^g   Caenepeel, Philippe ^a   Louis, Edouard ^c   Van Assche, Gert ^h  

^a H Hart ziekenhuis Roeselare Menen ^*  (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Imelda GI Clinical Research Centre   (Belgium)

^f ERASME HOSPITAL   (Belgium)

^g UCL Bruxelles   (Belgium)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

ADA; Adalimumab; Crohn's disease; Dose de escalation; Dose escalation

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CROHN DISEASE; DRUG DOSE ESCALATION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84872487090     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.03.018     Document Type: Article

References (13)

1. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130(2):323-333.
2. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007 Jun 19, 146(12):829-838.
3. Karmiris K., Paintaud G., Noman M., Magdelaine-Beuzelin C., Ferrante M., Degenne D., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009 Nov, 137(5):1628-1640.
4. Swoger J.M., Loftus E.V., Tremaine W.J., Faubion W.A., Pardi D.S., Kane S.V., et al. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis 2010 Nov, 16(11):1912-1921.
5. Ho G.T., Mowat A., Potts L., Cahill A., Mowat C., Lees C.W., et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther 2009 Mar 1, 29(5):527-534.
6. Russo E.A., Iacucci M., Lindsay J.O., Campbell S., Hart A., Hamlin J., et al. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Eur J Gastroenterol Hepatol 2010 Mar, 22(3):334-339.
7. Swaminath A., Ullman T., Rosen M., Mayer L., Lichtiger S., Abreu M.T. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. Aliment Pharmacol Ther 2009 Feb 1, 29(3):273-278.
8. Issa M., Zadvornova Y., Naik A.S., Stein D.J., Venu N., Perera L.P. High rates of dose escalation and termination of adalimumab therapy in patients exposed to infliximab. Gastroenterology 2011, (Ab Mo1227).
9. Van der Valk ME, van Oijen M.G., Siersema P.D., Ammerlaan M.J., Oldenburg B. Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators: results from a nationwide study in the Netherlands. Gastroenterology 2011, (Abstract DDW Sa 1247).
10. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007 Jul, 66(7):921-926. (Epub 2007 Feb 14).
11. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010 Apr 15, 362(15):1383-1395.
12. Jürgens M., Mahachie John J.M., Cleynen I., Schnitzler F., Fidder H., van Moerkercke W., et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011 May, 9(5):421-427.
13. Löfberg R., Louis E.V., Reinisch W., Robinson A.M., Kron M., Camez A., et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis 2012 Jan, 18(1):1-9.